Scholarlink

<p>Polycythemia vera (PV) is a chronic myeloproliferative neoplasm characterized by erythrocytosis, thrombotic risk, and JAK2-driven clonal proliferation. Data from North India on real-world clinical profile and treatment outcomes remain limited. This single-center retrospective study included 40 adult PV patients diagnosed between January 2018 and June 2024 with a minimum follow-up of 6 months. Clinical characteristics, mutation status, treatment patterns, hematocrit (HCT) control, and overall survival were analyzed using descriptive statistics and Kaplan–Meier survival analysis. The mean age was 52.2 ± 14.3 years with female predominance (57.5%). Prior thrombosis occurred in 20% of patients, and 40% were high-risk. JAK2 mutation was detected in 92.5% of cases. Hydroxyurea with phlebotomy was the most common first-line therapy (45%). Cytoreductive therapy was mainly initiated for age &gt; 60 years (32.5%) and inadequate HCT control (30%). Median HCT decreased to 42–44% during follow-up, although intermittent elevations persisted. No thrombotic or bleeding events occurred in low-risk patients, and one death occurred in the high-risk group. Five-year overall survival was 95.8% in low-risk and 93.8% in high-risk patients. PV patients in North India show younger age and favorable short-term survival, but sustained HCT control remains challenging, highlighting the need for optimized risk-adapted therapy and long-term follow-up.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Clinical Profile and Treatment Outcomes of Polycythemia Vera: A Single-Center Retrospective Study from North India

  • 期刊论文

  • 发表日期：

    2026年6月16日

查看全文
  • Raj Kumar Maurya,
  • S. P. Verma,
  • S. Nityanand,
  • R. Kushwaha,
  • S. Sinha,
  • P. Raghuveer,
  • A Middinti,
  • G. Datta,
  • A. Saha,
  • A. Shukla,
  • M. Kumar,
  • K. Kumari

摘要

Polycythemia vera (PV) is a chronic myeloproliferative neoplasm characterized by erythrocytosis, thrombotic risk, and JAK2-driven clonal proliferation. Data from North India on real-world clinical profile and treatment outcomes remain limited. This single-center retrospective study included 40 adult PV patients diagnosed between January 2018 and June 2024 with a minimum follow-up of 6 months. Clinical characteristics, mutation status, treatment patterns, hematocrit (HCT) control, and overall survival were analyzed using descriptive statistics and Kaplan–Meier survival analysis. The mean age was 52.2 ± 14.3 years with female predominance (57.5%). Prior thrombosis occurred in 20% of patients, and 40% were high-risk. JAK2 mutation was detected in 92.5% of cases. Hydroxyurea with phlebotomy was the most common first-line therapy (45%). Cytoreductive therapy was mainly initiated for age > 60 years (32.5%) and inadequate HCT control (30%). Median HCT decreased to 42–44% during follow-up, although intermittent elevations persisted. No thrombotic or bleeding events occurred in low-risk patients, and one death occurred in the high-risk group. Five-year overall survival was 95.8% in low-risk and 93.8% in high-risk patients. PV patients in North India show younger age and favorable short-term survival, but sustained HCT control remains challenging, highlighting the need for optimized risk-adapted therapy and long-term follow-up.